Geographic Atrophy Drug Market Report 2034: Epidemiology, Latest FDA Approvals | Aviceda Therapeutics, Iveric Bio, Alkeus Pharmaceuticals, Allegro Ophthalmics, Stealth BioTherapeutics, Novartis

DelveInsight's "Geographic Atrophy Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Geographic Atrophy, historical and forecasted epidemiology as well as the Geographic Atrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Discover which therapies are expected to grab the Geographic Atrophy Market Share @ Geographic Atrophy Market Outlook- https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Geographic Atrophy Market Report
• The increase in Geographic Atrophy Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Geographic Atrophy Market is anticipated to witness growth at a considerable CAGR.
• According to DelveInsight's estimates, the US accounted for around 700,000 Geographic Atrophy prevalent cases in 2023
• In geographic atrophy cases, moderate-to-severe visual impairment is predominant accounted for more than 40%, while occurrences requiring surgery or leading to legal blindness are less common.
• The leading Geographic Atrophy Companies working in the market include Aviceda Therapeutics, Iveric Bio, Alkeus Pharmaceuticals, Allegro Ophthalmics, Stealth BioTherapeutics, Novartis, Perceive Biotherapeutics, Inc., Genentech, Inc., NGM Biopharmaceuticals, Inc, Annexon, Inc., Regenerative Patch Technologies, LLC, Apellis Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Astellas Pharma Inc, Gyroscope Therapeutics Limited, and others.
• Promising Geographic Atrophy Pipeline Therapies in the various stages of development include AVD-104, Zimura (avacincaptad pegol), ALK-001, Risuteganib, Elamipretide, PPY988, VOY-101, OpRegen, NGM621, ANX007, CPCB-RPE1, APL-2, IONIS-FB-LRx, ASP7317, GT005, and others.
• In April 2024, Ocugen announced that the data and safety monitoring board (DSMB) for the Phase I/II clinical trial for OCU410 recently convened and approved to proceed dosing with the medium dose of OCU410 for geographic atrophy.
• In January 2024, Apellis Pharmaceuticals announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a negative opinion on the Marketing Authorization Application of intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to AMD.

Download the report to understand which factors are driving Geographic Atrophy Epidemiology trends @ Geographic Atrophy Epidemiological Insights- https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Geographic Atrophy Overview
Geographic atrophy (GA) is a medical condition that affects the retina, which is the light-sensitive layer at the back of the eye. It's a form of age-related macular degeneration (AMD), which is a leading cause of vision loss in people over 50. In GA, there's a gradual breakdown of cells in the macula, the central part of the retina responsible for sharp, central vision.

Geographic Atrophy Epidemiology Segmentation in the 7MM
• Total Geographic Atrophy Prevalent Cases
• Geographic Atrophy Late Stage-specific Prevalent Cases
• Total Geographic Atrophy Diagnosed Prevalent Cases
• Geographic Atrophy Age-specific Cases
• Geographic Atrophy Cases by Visual Impairment

To know more about Geographic Atrophy treatment guidelines, visit @ Geographic Atrophy Treatment Market Landscape- https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Geographic Atrophy Market Insights
Geographic atrophy, the advanced stage of dry AMD, has emerged as a prominent focus of research. Current investigations predominantly center on therapies targeting complement inhibitors of C3 and C5, pivotal factors in triggering inflammation and subsequent cell death within the eye. Extensive studies led by the National Eye Institute and esteemed researchers globally have unveiled the likelihood of an overactive complement system as a central player in the genesis of dry AMD and its evolution toward geographic atrophy.

Geographic Atrophy Treatment Market Landscape
The Geographic Atrophy treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Geographic Atrophy has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

Learn more about the FDA-approved drugs for Geographic Atrophy @ Drugs for Geographic Atrophy Treatment- https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Geographic Atrophy Drugs Uptake
• IZERVAY, developed by Astellas Pharma/Iveric Bio is designed to target and inhibit complement factor C5. IZERVAY binds to C5 and inhibits its cleavage into the terminal fragments C5a and C5b. In August 2023, the US FDA approved IZERVAY for the treatment of geographic atrophy secondary to AMD.
• SYFOVRE, developed by Apellis Pharmaceuticals is a targeted C3 inhibitor designed to regulate excessive complement activation, which can lead to the onset and progression of many serious diseases. Pegcetacoplan is a type of synthetic cyclic peptide conjugated to a polyethylene glycol polymer that binds specifically to C3 and C3b. In February 2023, the US FDA approved SYFOVRE for the treatment of geographic atrophy secondary to AMD.

Geographic Atrophy Market Dynamics
The Geographic Atrophy market dynamics are expected to change in the coming years. Payers' willingness to pay is assumed to be strong since the unavailability of approved medicines creates a high unmet demand and the possibility of avoiding progression to wet AMD, which is associated with high treatment costs. Moreover, due to the existing absence of competitive therapies, clinical outcome requirements may be minimal; hence, sham or placebo-controlled clinical trials may suffice for initial entrants. Furthermore, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the geographic atrophy market in the 7MM.

Major Geographic Atrophy Companies
Aviceda Therapeutics, Iveric Bio, Alkeus Pharmaceuticals, Allegro Ophthalmics, Stealth BioTherapeutics, Novartis, Perceive Biotherapeutics, Inc., Genentech, Inc., NGM Biopharmaceuticals, Inc, Annexon, Inc., Regenerative Patch Technologies, LLC, Apellis Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Astellas Pharma Inc, Gyroscope Therapeutics Limited, and others.

Scope of the Geographic Atrophy Market Report
• Coverage- 7MM
• Geographic Atrophy Companies- Aviceda Therapeutics, Iveric Bio, Alkeus Pharmaceuticals, Allegro Ophthalmics, Stealth BioTherapeutics, Novartis, Perceive Biotherapeutics, Inc., Genentech, Inc., NGM Biopharmaceuticals, Inc, Annexon, Inc., Regenerative Patch Technologies, LLC, Apellis Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Astellas Pharma Inc, Gyroscope Therapeutics Limited, and others.
• Geographic Atrophy Therapies- AVD-104, Zimura (avacincaptad pegol), ALK-001, Risuteganib, Elamipretide, PPY988, VOY-101, OpRegen, NGM621, ANX007, CPCB-RPE1, APL-2, IONIS-FB-LRx, ASP7317, GT005, and others.
• Geographic Atrophy Market Dynamics: Geographic Atrophy Market Drivers and Barriers
• Geographic Atrophy Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Geographic Atrophy Drugs in development @ Geographic Atrophy Clinical Trials Assessment- https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Geographic Atrophy Executive Summary
3. Competitive Intelligence Analysis for Geographic Atrophy
4. Geographic Atrophy: Market Overview at a Glance
5. Geographic Atrophy: Disease Background and Overview
6. Geographic Atrophy Patient Journey
7. Geographic Atrophy Epidemiology and Patient Population
8. Geographic Atrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Geographic Atrophy Unmet Needs
10. Key Endpoints of Geographic Atrophy Treatment
11. Geographic Atrophy Marketed Products
12. Geographic Atrophy Emerging Therapies
13. Geographic Atrophy: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Geographic Atrophy Market Outlook
16. Geographic Atrophy Market Access and Reimbursement Overview
17. Geographic Atrophy KOL Views
18. Geographic Atrophy Market Drivers
19. Geographic Atrophy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.